TACE plus Lenvatinib and Envafolimab for Unresectable HCC: A Prospective Pilot Study

Supplementary file 1 from a single-arm pilot study investigating the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and envafolimab for conversion therapy in unresectable hepatocellular carcinoma (HCC). The dataset, authored by Yuhao Su and shared under CC-BY-4.0, contains results from 15 patients enrolled between April and September 2024, with a median follow-up of 16 months.

Use Cases

• Analyze conversion-to-resection rates based on the primary endpoint of the pilot study.
• Evaluate objective and disease control response rates based on mRECIST criteria.
• Assess progression-free and overall survival outcomes based on the reported median PFS and OS rates.
• Review treatment-emergent adverse event profiles, including gastrointestinal bleeding, based on the safety data.

Strengths

• Dataset is associated with a registered clinical trial (ChiCTR2400081945).
• Results are based on a specific cohort of 15 patients with Barcelona Clinic Liver Cancer stage B or C HCC.
• Includes multiple clinical endpoints: conversion rate, ORR, DCR, pathological response, PFS, and OS.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The study design is a single-arm pilot with a limited sample size of 15 patients, as noted in the description.

Provenance

Source

Yuhao Su, via figshare.

Collection Method

Data collected from a single-center, open-label, single-arm pilot clinical trial.

Time Range

Patient enrollment occurred between April and September 2024.

Freshness

Last updated 2026-04-22 05:47:27; freshness should be verified.